FR22C1021I1 - Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif - Google Patents

Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif

Info

Publication number: FR22C1021I1
Authority: FR; France
Prior art keywords: ponesimod; selective; receptor agonist; dosage regimen; regimen
Prior art date: 2014-12-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR22C1021C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Actelion Pharmaceuticals Ltd

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-11

Filing date

2022-06-01

Publication date

2022-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54843844&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1021(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2022-06-01 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2022-07-15 Publication of FR22C1021I1 publication Critical patent/FR22C1021I1/fr

2023-04-14 Application granted granted Critical

2023-04-14 Publication of FR22C1021I2 publication Critical patent/FR22C1021I2/fr

Status Active legal-status Critical Current

Links

LPAUOXUZGSBGDU-ULCCENQXSA-N (5z)-5-[[3-chloro-4-[(2r)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=NCCC)S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-ULCCENQXSA-N 0.000 title 1
102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
229950009275 ponesimod Drugs 0.000 title 1
239000000018 receptor agonist Substances 0.000 title 1
229940044601 receptor agonist Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Endocrinology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Oncology (AREA)
Otolaryngology (AREA)

FR22C1021C 2014-12-11 2022-06-01 Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif Active FR22C1021I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP2014077469		2014-12-11
EP2015058202		2015-04-15
PCT/EP2015/079208 WO2016091996A1 (fr)	2014-12-11	2015-12-10	Régime posologique pour un agoniste de récepteur s1p1 sélectif

Publications (2)

Publication Number	Publication Date
FR22C1021I1 true FR22C1021I1 (fr)	2022-07-15
FR22C1021I2 FR22C1021I2 (fr)	2023-04-14

Family

ID=54843844

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR22C1021C Active FR22C1021I2 (fr)	2014-12-11	2022-06-01	Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif

Country Status (31)

Country	Link
US (4)	US10220023B2 (fr)
EP (2)	EP3256125B1 (fr)
JP (1)	JP6244497B1 (fr)
KR (4)	KR102427123B1 (fr)
CN (2)	CN117137912A (fr)
AU (2)	AU2015359346B2 (fr)
CA (1)	CA2968180C (fr)
CL (1)	CL2017001457A1 (fr)
CY (1)	CY1125170T1 (fr)
DK (1)	DK3256125T3 (fr)
EA (1)	EA036075B1 (fr)
ES (1)	ES2909071T3 (fr)
FR (1)	FR22C1021I2 (fr)
HR (1)	HRP20220359T8 (fr)
HU (2)	HUE057865T2 (fr)
IL (1)	IL252727B (fr)
LT (2)	LT3256125T (fr)
MX (2)	MX2020011182A (fr)
MY (1)	MY188764A (fr)
NL (1)	NL301174I2 (fr)
NO (1)	NO2022023I1 (fr)
PH (1)	PH12017501059A1 (fr)
PL (1)	PL3256125T3 (fr)
PT (1)	PT3256125T (fr)
RS (1)	RS63048B1 (fr)
SG (1)	SG11201704563RA (fr)
SI (1)	SI3256125T1 (fr)
TW (1)	TW201625242A (fr)
UA (1)	UA122064C2 (fr)
WO (1)	WO2016091996A1 (fr)
ZA (1)	ZA201704624B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2009227629B2 (en)	2008-03-17	2014-09-04	Actelion Pharmaceuticals Ltd	Dosing regimen for a selective S1P1 receptor agonist
MA41139A (fr)	2014-12-11	2017-10-17	Actelion Pharmaceuticals Ltd	Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
WO2016091996A1 (fr)	2014-12-11	2016-06-16	Actelion Pharmaceuticals Ltd	Régime posologique pour un agoniste de récepteur s1p1 sélectif
JOP20190207A1 (ar) *	2017-03-14	2019-09-10	Actelion Pharmaceuticals Ltd	تركيبة صيدلانية تشتمل على بونيسيمود
US11013723B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014940B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Thiazolidinone and oxazolidinone compounds and formulations
US11186556B1 (en)	2018-10-16	2021-11-30	Celgene Corporation	Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
CA3145269A1 (fr)	2019-07-22	2021-01-28	Michel BURCKLEN	Utilisation du ponesimod dans le traitement de la sclerose en plaques
EP4051250A1 (fr)	2019-10-31	2022-09-07	Idorsia Pharmaceuticals Ltd	Combinaison d'un antagoniste de cxcr7 avec un modulateur du récepteur s1p1
BR112022017754A2 (pt)	2020-03-06	2022-10-18	Actelion Pharmaceuticals Ltd	Métodos para retardar a perda de volume cerebral
BR112023018841A2 (pt)	2021-03-17	2023-12-26	Actelion Pharmaceuticals Ltd	Sistema de dosagem farmacêutica
CA3220723A1 (fr)	2021-10-11	2023-04-20	Allitia DIBERNARDO	Methodes de traitement de la sclerose en plaques
WO2023061935A1 (fr)	2021-10-11	2023-04-20	Actelion Pharmaceuticals Ltd	Méthodes de traitement de la sclérose en plaques
WO2023062511A1 (fr)	2021-10-11	2023-04-20	Actelion Pharmaceuticals Ltd	Méthodes de traitement de la sclérose en plaques
WO2023061918A1 (fr)	2021-10-11	2023-04-20	Actelion Pharmaceuticals Ltd	Méthodes de traitement de la sclérose en plaques
WO2023079079A1 (fr)	2021-11-05	2023-05-11	Actelion Pharmaceuticals Ltd	Méthodes de traitement de la sclérose en plaques
CA3220702A1 (fr)	2022-02-11	2023-08-17	Actelion Pharmaceuticals Ltd	Methodes de ralentissement d'une augmentation du volume ventriculaire cerebral

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0217152D0 (en)	2002-07-24	2002-09-04	Novartis Ag	Organic compounds
USRE43833E1 (en)	2003-11-21	2012-11-27	Actelion Pharmaceuticals Ltd.	Thiazolidin-4-one derivatives
CN100567275C (zh)	2003-11-21	2009-12-09	埃科特莱茵药品有限公司	作为免疫抑制剂的5-(苯基-(z)-亚基)-噻唑烷-4-酮衍生物
KR20070085465A (ko)	2004-11-29	2007-08-27	노파르티스 아게	Ｓ１ｐ 수용체 효능제의 투여 용법
US7879821B2 (en)	2006-01-26	2011-02-01	University Of Medicine And Dentistry Of New Jersey	Method for modulating inflammatory responses by altering plasma lipid levels
MX2009005048A (es)	2006-11-23	2009-05-25	Actelion Pharmaceuticals Ltd	Nuevo proceso para la preparacion de derivados de 2-imino-tiazolidin-4-ona.
US8912340B2 (en)	2006-11-23	2014-12-16	Actelion Pharmaceuticals Ltd.	Process for the preparation of 2-imino-thiazolidin-4-one derivatives
AU2009227629B2 (en)	2008-03-17	2014-09-04	Actelion Pharmaceuticals Ltd	Dosing regimen for a selective S1P1 receptor agonist
GB0819182D0 (en)	2008-10-20	2008-11-26	Actelion Pharmaceuticals Ltd	Crystalline forms
SI2379069T1 (sl)	2008-12-22	2015-07-31	Novartis Ag	Režim odmerjanja agonista receptorja S1P
ES2760607T3 (es)	2008-12-22	2020-05-14	Novartis Ag	Régimen de dosificación para un agonista del receptor s1p
JP6322630B2 (ja)	2012-08-17	2018-05-09	アクテリオンファーマシューティカルズリミテッドＡｃｔｅｌｉｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓＬｔｄ	（２Ｚ，５Ｚ）−５−（３−クロロ−４−（（Ｒ）−２，３−ジヒドロキシプロポキシ）ベンジリデン）−２−（プロピルイミノ）−３−（ｏ−トリル）チアゾリジン−４−オンの製造方法及び前記方法において使用される中間体
MA41139A (fr)	2014-12-11	2017-10-17	Actelion Pharmaceuticals Ltd	Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
WO2016091996A1 (fr) *	2014-12-11	2016-06-16	Actelion Pharmaceuticals Ltd	Régime posologique pour un agoniste de récepteur s1p1 sélectif

2015
- 2015-12-10 WO PCT/EP2015/079208 patent/WO2016091996A1/fr active Application Filing
- 2015-12-10 KR KR1020177018950A patent/KR102427123B1/ko active IP Right Grant
- 2015-12-10 SI SI201531811T patent/SI3256125T1/sl unknown
- 2015-12-10 RS RS20220283A patent/RS63048B1/sr unknown
- 2015-12-10 EP EP15807916.0A patent/EP3256125B1/fr active Active
- 2015-12-10 KR KR1020207002611A patent/KR20200013086A/ko not_active Application Discontinuation
- 2015-12-10 PT PT158079160T patent/PT3256125T/pt unknown
- 2015-12-10 CA CA2968180A patent/CA2968180C/fr active Active
- 2015-12-10 SG SG11201704563RA patent/SG11201704563RA/en unknown
- 2015-12-10 AU AU2015359346A patent/AU2015359346B2/en active Active
- 2015-12-10 JP JP2017531167A patent/JP6244497B1/ja active Active
- 2015-12-10 MX MX2020011182A patent/MX2020011182A/es unknown
- 2015-12-10 KR KR1020237034975A patent/KR20230147768A/ko not_active Application Discontinuation
- 2015-12-10 KR KR1020217032617A patent/KR102590068B1/ko active IP Right Grant
- 2015-12-10 UA UAA201707086A patent/UA122064C2/uk unknown
- 2015-12-10 MX MX2017007638A patent/MX2017007638A/es unknown
- 2015-12-10 ES ES15807916T patent/ES2909071T3/es active Active
- 2015-12-10 PL PL15807916T patent/PL3256125T3/pl unknown
- 2015-12-10 EA EA201791286A patent/EA036075B1/ru unknown
- 2015-12-10 EP EP22152212.1A patent/EP4056179A1/fr active Pending
- 2015-12-10 HU HUE15807916A patent/HUE057865T2/hu unknown
- 2015-12-10 MY MYPI2017702097A patent/MY188764A/en unknown
- 2015-12-10 CN CN202310732054.6A patent/CN117137912A/zh active Pending
- 2015-12-10 US US15/534,929 patent/US10220023B2/en active Active
- 2015-12-10 HR HRP20220359TT patent/HRP20220359T8/hr unknown
- 2015-12-10 TW TW104141578A patent/TW201625242A/zh unknown
- 2015-12-10 CN CN201580067209.2A patent/CN106999461A/zh active Pending
- 2015-12-10 DK DK15807916.0T patent/DK3256125T3/da active
- 2015-12-10 LT LTEPPCT/EP2015/079208T patent/LT3256125T/lt unknown
2017
- 2017-06-06 IL IL252727A patent/IL252727B/en active IP Right Grant
- 2017-06-07 PH PH12017501059A patent/PH12017501059A1/en unknown
- 2017-06-08 CL CL2017001457A patent/CL2017001457A1/es unknown
- 2017-07-10 ZA ZA2017/04624A patent/ZA201704624B/en unknown
2019
- 2019-01-29 US US16/261,327 patent/US10857134B2/en active Active
2020
- 2020-04-22 AU AU2020202684A patent/AU2020202684A1/en not_active Abandoned
- 2020-11-05 US US17/090,756 patent/US11771683B2/en active Active
2022
- 2022-04-07 CY CY20221100260T patent/CY1125170T1/el unknown
- 2022-05-09 NL NL301174C patent/NL301174I2/nl unknown
- 2022-05-12 HU HUS2200021C patent/HUS2200021I1/hu unknown
- 2022-05-20 LT LTPA2022505C patent/LTPA2022505I1/lt unknown
- 2022-06-01 FR FR22C1021C patent/FR22C1021I2/fr active Active
- 2022-06-10 NO NO2022023C patent/NO2022023I1/no unknown
- 2022-10-13 US US18/046,492 patent/US20230131600A1/en active Pending

Also Published As

Publication number	Publication date
ZA201704624B (en)	2022-03-30
DK3256125T3 (da)	2022-03-21
CA2968180C (fr)	2020-01-28
LT3256125T (lt)	2022-04-11
EA201791286A1 (ru)	2017-12-29
SI3256125T1 (sl)	2022-04-29
WO2016091996A1 (fr)	2016-06-16
NO2022023I1 (no)	2022-06-10
JP6244497B1 (ja)	2017-12-06
NZ768672A (en)	2023-10-27
NL301174I2 (nl)	2022-06-09
HRP20220359T1 (hr)	2022-05-13
HUE057865T2 (hu)	2022-06-28
US20230131600A1 (en)	2023-04-27
SG11201704563RA (en)	2017-07-28
CY1125170T1 (el)	2022-07-22
UA122064C2 (uk)	2020-09-10
AU2015359346B2 (en)	2020-05-07
KR102590068B1 (ko)	2023-10-16
US20170319555A1 (en)	2017-11-09
AU2020202684A1 (en)	2020-05-14
EP3256125A1 (fr)	2017-12-20
IL252727B (en)	2021-02-28
ES2909071T3 (es)	2022-05-05
HUS2200021I1 (hu)	2022-05-28
RS63048B1 (sr)	2022-04-29
EP3256125B1 (fr)	2022-01-26
AU2015359346A8 (en)	2017-08-03
KR20210126792A (ko)	2021-10-20
NZ733463A (en)	2023-10-27
US11771683B2 (en)	2023-10-03
NL301174I1 (fr)	2022-05-09
KR20230147768A (ko)	2023-10-23
AU2015359346A1 (en)	2017-07-27
US10220023B2 (en)	2019-03-05
US20180147188A9 (en)	2018-05-31
TW201625242A (zh)	2016-07-16
CN117137912A (zh)	2023-12-01
FR22C1021I2 (fr)	2023-04-14
EP4056179A1 (fr)	2022-09-14
PT3256125T (pt)	2022-05-06
IL252727A0 (en)	2017-08-31
MX2020011182A (es)	2022-10-03
EA036075B1 (ru)	2020-09-23
PL3256125T3 (pl)	2022-05-09
KR102427123B1 (ko)	2022-07-28
MX2017007638A (es)	2017-09-11
US20190151292A1 (en)	2019-05-23
KR20170094335A (ko)	2017-08-17
JP2017538706A (ja)	2017-12-28
KR20200013086A (ko)	2020-02-05
PH12017501059A1 (en)	2017-11-27
CL2017001457A1 (es)	2018-02-09
HRP20220359T8 (hr)	2022-05-27
CN106999461A (zh)	2017-08-01
US20210052555A1 (en)	2021-02-25
US10857134B2 (en)	2020-12-08
MY188764A (en)	2021-12-30
CA2968180A1 (fr)	2016-06-16
LTPA2022505I1 (fr)	2022-06-10

Publication	Publication Date	Title
FR22C1021I2 (fr)	2023-04-14	Régime posologique pour ponesimod, un agoniste du récepteur s1p1 sélectif
HK1257825A1 (zh)	2019-11-01	檢測網絡內的位置
IL288907A (en)	2022-02-01	A pharmaceutical combination containing a selective s1p1 receptor agonist
PL3067774T3 (pl)	2018-07-31	Urządzenie operacyjne do maszyny budowlanej
DK3212637T3 (da)	2021-07-12	Dopamin-d3-receptorantagonistforbindelser
IL247084B (en)	2019-09-26	dose fgh–18
GB201418710D0 (en)	2014-12-03	Dosage regimen
RS61323B1 (sr)	2021-02-26	Dozirna pumpa za dozirni uređaj kao i dozirni uređaj
DK3362446T3 (da)	2021-01-04	Dopamin-d3-receptorantagonister med en morpholindel
FR3046350B1 (fr)	2018-02-16	Chariot- portoir pour un brancard.
HUP1500110A2 (hu)	2016-09-28	Vízerõgép áramló közeghez
TH1601000316A (th)	2018-02-01	อะโกนิสต์ของตัวรับวาโซเพรสซิน-2
GB201501974D0 (en)	2015-03-25	Network subscription for a new device
GB201419430D0 (en)	2014-12-17	Dopamine D3 receptor antagonist compounds
GB201419433D0 (en)	2014-12-17	Dopamine D3 receptor antagonist compounds
TH1601002277A (th)	2017-08-24	เครื่องจักรสำหรับจ่ายภาชนะ
GB201418708D0 (en)	2014-12-03	Dosage regimen
ES1134965Y (es)	2015-03-20	Máquina dispensadora de bebidas mediante dosificación
GB201400171D0 (en)	2014-02-19	Dosage regimen